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Deletion of RAGE fails to prevent 
hepatosteatosis in obese mice 
due to impairment of other AGEs 
receptors and detoxifying systems
Kristiaan Wouters1,2, Alessia S. Cento3, Katrien H. Gaens1,2, Margee Teunissen1, 
Jean L. J. M. Scheijen1,2, Federica Barutta4, Fausto Chiazza5, Debora Collotta6, 
Manuela Aragno3, Gabriella Gruden4, Massimo Collino6, Casper G. Schalkwijk1,2,7 & 
Raffaella Mastrocola1,3,7*
Advanced glycation endproducts (AGEs) are involved in several diseases, including NAFLD and NASH. 
RAGE is the main receptor mediating the pro-inflammatory signalling induced by AGEs. Therefore, 
targeting of RAGE has been proposed for prevention of chronic inflammatory diseases. However, the 
role of RAGE in the development of NAFLD and NASH remains poorly understood. We thus aimed 
to analyse the effect of obesity on AGEs accumulation, AGE-receptors and AGE-detoxification, and 
whether the absence of RAGE might improve hepatosteatosis and inflammation, by comparing the 
liver of lean control, obese (LeptrDb−/−) and obese RAGE-deficient (RAGE−/− LeptrDb−/−) mice. 
Obesity induced AGEs accumulation and RAGE expression with hepatosteatosis and inflammation 
in LeptrDb−/−, compared to lean controls. Despite the genetic deletion of RAGE in the LeptrDb−/− 
mice, high levels of intrahepatic AGEs were maintained accompanied by decreased expression of the 
protective AGE-receptor-1, impaired AGE-detoxifying system glyoxalase-1, and increased expression 
of the alternative AGE-receptor galectin-3. We also found sustained hepatosteatosis and inflammation 
as determined by persistent activation of the lipogenic SREBP1c and proinflammatory NLRP3 
signalling pathways. Thus, RAGE targeting is not effective in the prevention of NAFLD in conditions of 
obesity, likely due to the direct liver specific crosstalk of RAGE with other AGE-receptors and AGE-
detoxifying systems.
Advanced glycation endproducts (AGEs) are toxic compounds produced from reactions between proteins and 
sugars or fatty  acids1. AGEs are known to be involved in the development of diabetic complications through 
receptor-mediated activation of intracellular inflammatory  signalling2. Recently, accumulation of AGEs in adi-
pose tissue has been linked to the onset of metabolic  diseases3,4. In particular, plasma carboxymethyllysine 
(CML), one of the best characterized AGEs, has been demonstrated to be preferentially trapped in adipose tis-
sue through the binding with the receptor for AGEs (RAGE)5, leading to the activation of proinflammatory and 
prooxidant signalling that can interfere with peripheral insulin  sensitivity6.
RAGE is a member of the superfamily of Ig molecules and belongs to the class of type I cell-surface  receptors7. 
RAGE engages numerous ligands including AGEs and exhibits broad expression on many cell  types8. Generally, 
RAGE activates NFkB, but its expression is in turn under control of NFkB, thus representing a positive feedback 
for further increased RAGE  expression9,10. In a physiological state RAGE is expressed at low  levels11, but patho-
physiological conditions, such as diabetes, chronic inflammation, or obesity, induce increased RAGE expression 
in different tissues, such as vasculature, adipose tissue and  liver10. Although sustained activation of RAGE during 
pathological events results in inflammation and promotes the development of complications, targeting RAGE 
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as a therapeutic treatment remains controversial because in physiological conditions RAGE plays a key role in 
both innate and adaptive immune  responses12.
Genetic deletion of RAGE has been widely used to investigate the beneficial effects of RAGE targeting. The 
deletion of RAGE in rodent models of diabetes and diet-induced obesity has been demonstrated to be effective 
in reduction of vascular  complications13,  atherosclerosis14,15, kidney  disease16,17, and synaptic injury in  brain18. 
Moreover, in the obese mouse model LeptrDb−/−, the genetic deletion of RAGE has been shown to reduce CML 
accumulation in adipose tissue, as well as circulating cytokines and adipokines, ameliorating insulin  resistance5.
However, little is known about the effect of RAGE deletion in liver, which is one of the main organs involved 
in glucose and lipid metabolism. Indeed, the expression of RAGE is often reported to be increased in associa-
tion to AGEs accumulation during the development of hepatic steatosis and inflammation in both animals and 
humans, suggesting a key role for the AGE-RAGE signalling in NAFLD and  NASH19,20. Specifically, it has been 
proposed that AGEs could contribute to the progression from NAFLD to NASH by RAGE-dependently activat-
ing pro-inflammatory and pro-fibrotic signallings. However, since AGEs levels are already elevated upon the 
appearance of steatosis, we may speculate that AGEs exert a primary role in the onset of NAFLD by affecting 
hepatic lipid  metabolism19,21.
However, conflicting data have been reported about the prominent role of RAGE in the development of these 
diseases and the efficacy of RAGE deletion, depending on the experimental model  used22. It has been demon-
strated that the blockade of RAGE in CML-treated hepatocytes prevents hepatocytes  inflammation20 and that 
hepatocyte-specific RAGE deletion attenuates NASH in an experimental mouse model fed with a high AGEs 
 diet23. On the contrary, whole-body deletion of RAGE in a model of cholesterol-induced NASH in hyperlipidemic 
 mice24 did not improve either lipids accumulation or  inflammation22, indicating that AGEs may participate in 
the development of NAFLD and NASH pathogenesis through multiple mechanisms.
In addition to RAGE, the liver expresses various other AGE receptors including the AGE-receptor 1 (AGE-
R1) and galectin-3 (Gal-3)25. Gal-3 has been associated with inflammation and liver fibrosis and its inhibition 
was able to reduce fibrosis in preclinical studies of  NASH26,27, although in a very recent clinical study the efficacy 
of Gal-3 inhibition has not been confirmed in human patients with NASH, cirrhosis and portal  hypertension28. 
Conversely, AGE-R1 is thought to be responsible for the detoxification and clearance of AGEs and for inhibi-
tion of AGE-RAGE-induced pro-inflammatory signalling and oxidative  stress29–31. A decline in the expression 
of AGE-R1 has been demonstrated to be associated with increases in plasma AGEs in both murine models 
and diabetic  patients30,32 and recently also in a RAGE-dependent manner in murine NASH and in the livers of 
human NASH  patients23.
In physiological conditions accumulation of AGEs in cells is also prevented by the activity of glyoxalases, 
the main AGE-detoxifying system acting to degrade methylglyoxal, a major precursor of AGEs, to d-lactate. In 
the glyoxalase system the glyoxalase-1 (Glo-1) represents the rate limiting step depending on the availability of 
reduced glutathione (GSH) recruited as  cofactor33. Impairment of Glo-1 detoxifying potential has been suggested 
to contribute to the AGEs-mediated tissue  damage33,34.
Thus, the role of RAGE in the development of NAFLD and NASH and the reciprocal relationships between 
RAGE and the other AGE-receptors and AGE-detoxifying systems in the liver needs further clarification.
In this study we aimed to analyse the impact of obesity-driven NAFLD on hepatic AGEs accumulation and 
on the expression of AGEs-binding receptors and detoxifying systems in the liver, and the role of RAGE in 
modulating NAFLD, hepatic AGEs and the AGE-receptors and AGE-detoxifying systems.
Results
RAGE deletion does not reduce AGEs in the liver of LeptrDb−/− mice. For our aims, we used 
a genetically-obese mouse model, i.e. mice lacking the leptin receptor (LeptrDb−/−), with or without addi-
tional deletion of RAGE (RAGE+/+LeptrDb−/−, RAGE−/− LeptrDb−/−), compared to wild type lean mice 
(RAGE+/+LeptrDb+/+). At 13 weeks of age, obese LeptrDb−/− animals displayed increased body and impaired 
glucose tolerance compared to lean LeptrDb+/+ controls. Although RAGE deletion ameliorated glucose homeo-
stasis and systemic inflammatory markers in obese LeptrDb−/− animals, it did not affect body weight (Supple-
mentary Table S3), as previously  described5.
PCR and western blotting analysis showed increased RNA expression and protein levels of RAGE in the liver 
of obese (RAGE+/+LeptrDb−/−) mice which were both effectively downregulated when RAGE gene was knocked 
down (Fig. 1a). In the liver of obese mice we found increased levels of different classes of AGEs: CML (Fig. 1b), 
methylglyoxal 5-hydro-5-methylimidazolones (MG-H1) (Fig. 1c), and carboxyethyllysine (CEL) (Fig. 1d), meas-
ured with state-of-the art UPLC-MSMS, as compared to lean control mice, which were unaffected by RAGE 
deletion (Fig. 1b–d).
The protein level and nuclear translocation of the pro-inflammatory transcription factor nuclear 
factor-kappa B (NFkBp65), one of the main targets of RAGE signalling, were increased in the obese 
RAGE+/+LeptrDb−/− mice, while both cytosolic and nuclear protein levels were completely abrogated in obese 
RAGE−/− LeptrDb−/− (Fig. 1e).
RAGE deletion does not prevent steatosis in the liver of LeptrDb−/− mice. Obese mice showed a 
marked focal macrovesicular steatosis. RAGE deletion did not prevent total hepatosteatosis in obese animals but 
caused a more diffuse microvescicular lipid droplet accumulation (Fig. 2a). Lipid accumulation was quantified 
by analysis of triglycerides and total cholesterol content in liver homogenates (Fig. 2b) showing that obesity-
induced accumulation of triglycerides is further enhanced in the absence of RAGE. We next determined the key 
proteins involved in the development of hepatic steatosis. In the liver of the obese LeptrDb−/− mice we found 
increased nuclear translocation of the sterol regulatory element binding protein-1c (SREBP1c) (Fig.  2c) and 
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Figure 1.  Receptor for advanced glycation endproducts (RAGE) expression and advanced glycation 
endproducts (AGEs) accumulation in liver. (a) PCR and Western blotting analysis for RAGE in liver mRNA 
and protein extracts from lean controls (RAGE+/+LeptrDb+/+), obese (RAGE+/+LeptrDb−/−), and RAGE 
KO obese (RAGE−/− LeptrDb−/−) mice. (b-d) Mass spectrometry analysis for carboxymethyllysine (CML) 
(b), methylglyoxal 5-hydro-5-methylimidazolones (MG-H1) (c), and carboxyethyllysine (CEL) (d) in liver 
lysates. (e) Western blotting analysis for cytosolic and nuclear levels of NFkBp65. Results are normalized for 
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Figure 2.  Hepatosteatosis. (a) Oil red O staining of 7 µm cryostatic sections of the liver from lean controls 
(RAGE+/+LeptrDb+/+), obese (RAGE+/+LeptrDb−/−), and RAGE KO obese (RAGE−/− LeptrDb−/−) mice 
showing hepatic lipids accumulation (20 × magnification). (b) Triglyceride and total cholesterol quantification in 
liver homogenates. (c) Western blotting analysis for the sterol regulatory element binding protein 1c (SREBP-1c) 
in nuclear extracts showing hepatic activation of lipogenesis. (d,e) Western blotting analysis for acetyl coenzyme 
A carboxylase (ACC) (d) and for fatty acids synthase (FASN) (e) in liver extracts. Data are means ± SEM of 4–6 
animals per group. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
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increased expression of the de novo lipid synthesis enzymes acetyl coenzyme A carboxylase (ACC) (Fig. 2d) and 
fatty acid synthase (FASN) (Fig. 2e), compared to the lean LeptrDb+/+ mice, which tended to be even further 
increased in obese RAGE−/−LeptrDb−/− mice (Fig. 2c–e).
RAGE deletion affects the expression of the AGEs-receptors AGE-R1 and Gal-3 in the liver of 
LeptrDb−/− mice. We next determined the expression of other receptors for AGEs in the liver. Obesity 
per se did not exert any effect on the gene and protein expression of the detoxifying AGE-receptor AGE-R1 
compared to the lean LeptrDb+/+ mice, while RAGE-deficient LeptrDb−/− mice displayed reduced AGE-R1 
expression (Fig. 3a).
Obese RAGE+/+LeptrDb−/− mice had significantly increased protein levels of the AGE-receptor Gal-3 in 
the liver, although no changes were seen at mRNA level, which was further exacerbated in RAGE−/−Lep-
trDb−/− mice in parallel with significantly increased gene expression (Fig. 3b).
RAGE deletion impairs the AGEs detoxifying enzymes Glo-1 and aldose reductase in the liver 
of LeptrDb−/− mice. Hepatic gene (Fig. 4a) and protein (Fig. 4b) expression, as well as enzymatic activ-
ity (Fig. 4c) of Glo-1, were not modified in obese RAGE+/+LeptrDb−/− compared to lean LeptrDb+/+ mice. 
Remarkably, RAGE-deficiency induced a downregulation of Glo-1 mRNA and protein (Fig. 4a,b). These changes 
were paralleled by impaired hepatic Glo-1 enzymatic activity (Fig.  4c), suggesting reduced detoxification of 
methylglyoxal in the liver of obese animals. In addition, we found that total glutathione, an essential cofactor 
for Glo-1, was reduced in obese animals compared to lean controls, independently of RAGE deletion (Fig. 4d).
Figure 3.  AGEs receptors. PCR and Western blotting analysis for AGE-receptor 1 (AGE-R1) (a) and 
galectin-3 (Gal-3) (b) in liver mRNA and protein extracts from lean controls (RAGE+/+LeptrDb+/+), obese 
(RAGE+/+LeptrDb−/−), and RAGE KO obese (RAGE−/− LeptrDb−/−) mice. Data are means ± SEM of 4–6 
animals per group. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
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In addition, the expression of aldose reductase, another enzyme described to be involved in the detoxifica-
tion of methylglyoxal, was reduced by obesity in both LeptrDb−/− groups without any modulation by RAGE 
deletion (Supplementary Fig. S1).
Different impact of RAGE deletion on the stress-activated pro-inflammatory pathways Nrf2 
and NLRP3 inflammasome in the liver of LeptrDb−/− mice. Next, we analysed the activation of the 
nuclear factor erythroid 2-related factor 2 (Nrf2). This transcription factor is important for the control of AGE-
R1 expression and for Glo-1 expression and activity, since it directly regulates the expression of GLO-1, but also 
regulates different reduced glutathione recycling enzymes that provide GSH to Glo-1 as co-factor for its enzy-
matic activity. Although mRNA expression of Nrf2 (Fig. 5a) was unaffected in obese RAGE+/+LeptrDb−/− and 
RAGE−/− LeptrDb−/− mice, nuclear protein levels of Nrf2 were increased in obese RAGE+/+LeptrDb−/− mice, 
suggesting enhanced transcriptional activity in obesity. This increase was completely absent in obese RAGE−/− 
LeptrDb−/− animals (Fig. 5b).
Finally, activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome complex was 
increased in the liver of the obese mice compared to lean controls, but it was not affected by RAGE deletion, 
demonstrated by the protein expression of NLRP3 (Fig. 5c), and by expression and cleavage activation of cas-
pase-1 (Fig. 5d) and interleukin-1β (IL-1β) (Fig. 5e). Since the main activator of the NLRP3 platform is NFkB, 
which activation is completely inhibited by the lacking of RAGE in our obese RAGE−/− mice, we analysed the 
Figure 4.  Glyoxalase-1 (Glo-1) expression and activity and glutathione levels. (a) PCR analysis for gene 
expression of Glo-1 in liver from lean controls (RAGE+/+LeptrDb+/+), obese (RAGE+/+LeptrDb−/−), and 
RAGE KO obese (RAGE−/− LeptrDb−/−) mice. (b) Western blotting analysis for Glo-1 protein levels in liver 
extracts. Histograms report the densitometric analysis normalized for β-actin content. (c) Glo-1 enzymatic 
activity detected in liver lysates. (d) Total glutathione in liver lysates. Data are means ± SEM of 4–6 animals per 
group. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 5.  Hepatic inflammation. (a) PCR analysis for gene expression of the nuclear factor erythroid 2-related 
factor 2 (Nrf2) in liver mRNA extracts. (b) Western blotting analysis for protein levels of Nrf2 in cytosolic and 
nuclear extracts of mice liver showing nuclear translocation. (c–f) Western blotting analysis for protein levels of 
the NLR family pyrin domain containing 3 (NLRP3) (c), active-caspase-1 (d), pro- and cleaved-intereleukin-1β 
(IL-1β) (e), myeloid differentiation primary response 88 (MyD88) (f) in liver protein extracts. Data are 
means ± SEM of 4–6 animals per group. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
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expression of myeloid differentiation primary response 88 (MyD88), an inducer of NLRP3 priming and activation 
alternative to NFkB. Although MyD88 was found to be markedly increased in the obese LeptrDb−/− groups, 
MyD88 was not affected by RAGE deletion (Fig. 5f).
Discussion
In this study we show in an animal model of obesity-induced NAFLD increased levels of hepatic AGEs, of 
RAGE expression and of Gal-3 protein amount, with no relevant modifications of other AGEs receptors and 
detoxification systems. Interestingly, deletion of RAGE neither prevented NAFLD development nor altered the 
accumulation of hepatic AGEs. In addition, RAGE deletion resulted in reduced AGE-R1 and Glo-1 and further 
increased Gal-3 receptor in the liver (Fig. 6). This reduced AGE-detoxifying potential and increased Gal-3 are 
most likely involved in the persistent hepatosteatosis and inflammation when RAGE is depleted and should be 
taken into account when investigating the role of the AGE-RAGE axis in liver pathologies.
A number of studies has shown that RAGE plays a role in toxic, ischaemic, and cholestatic liver  damage35–37. 
Neutralizing RAGE with specific antibodies has been reported to prevent hepatic stellate cells activation and 
fibrogenesis in a murine model of carbon tetrachloride-induced liver  fibrosis38. Moreover, blocking RAGE in 
hepatic stellate cells prevented the increase of AGEs-induced inflammatory and oxidative stress  markers39. 
Figure 6.  In healthy conditions, physiological levels of circulating AGEs bind to RAGE in the liver evoking a 
pro-inflammatory signaling. This effect is counteracted by the AGE-receptor-1 (AGE-R1) that competes with 
RAGE for AGEs binding and causes internalization and degradation of AGEs. The formation of endogenous 
AGEs is also inhibited by glyoxalase-1 (Glo-1) which detoxifies the AGE precursor methylglyoxal using reduced 
glutathione (GSH) as cofactor. In the liver of obese mice (RAGE+/+LeptrDb−/−) (left side of image) AGEs 
are produced in larger amounts and accumulate intracellularly. The expression of RAGE is greatly increased 
leading to activation of the NLRP3 inflammatory pathway. The presence of the alternative AGE receptor Gal-3 
is enhanced, but the detoxifying systems are not induced. The excess of intracellular AGEs activates the de novo 
lipid synthesis by interfering with the activity of the sterol regulatory element binding protein 1c (SREBP1c), 
contributing to hepatosteatosis. When RAGE is deleted in the obese background (RAGE−/− LeptrDb−/−) (right 
side of image), expression of galectin-3 (Gal-3) is further increased and is likely to be involved in a compensative 
AGEs trapping from the circulation and AGEs-induced NLRP3 inflammatory signalling. The lacking of RAGE is 
also associated in the liver with reduced AGE-R1 expression and Glo-1 activity that fail to detoxify intracellular 
AGEs, thus contributing to the maintenance of high hepatic AGEs levels, and prolonging SREBP1c activation 
and lipids accumulation. Thus, the deletion of RAGE fails to prevent AGE accumulation, hepatosteatosis and 
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Additionally, both systemic treatment with pyridoxamine and hepatocyte-specific RAGE deletion were shown 
to prevent NASH in a model relying on a high AGEs  diet23. In our study, we used mice with a homozygous muta-
tion in the leptin receptor (LeptrDb−/−) which are hyperphagic and are considered a good model of obesity 
and diabetes induced by excessive calories intake. The intrahepatic accumulation of MG-H1, CML, and CEL in 
the obese LeptrDb−/− mice were accompanied by increased expression of RAGE, activation of NFkB, and to 
activation of the SREBP1c lipogenic pathway, probably contributing to hepatosteatosis.
In accordance, it has been reported that CML accumulation in the liver of obese individuals is associated 
to hepatic pro-inflammatory genes expression and correlates with the grade of steatosis and  steatohepatitis20. 
The development of steatosis may have contributed to hepatic AGEs accumulation since FFAs stimulate CML 
accumulation in hepatocytes and subsequently elicit inflammatory reactions via  RAGE20. Although we found 
that the genetic deletion of RAGE is effective in lowering NFkB in the liver, it did not improve hepatic steatosis. 
In accordance, the genetic deletion of RAGE in the hyperlipidemic Ldlr−/− mouse model fed a western diet 
did not improve hepatosteatosis, nor systemic and hepatic inflammation, and did not reduce plasma and liver 
 AGEs22. Surprisingly, hepatocyte-specific deletion of RAGE was recently reported to reduce hepatic AGEs, liver 
inflammation and steatosis elicited by a diet rich in  AGEs23. It is known that RAGE is involved in trapping of CML 
selectively in adipose  tissue5 and that its deletion leads to reduced adipocyte size, adipose tissue expansion, and 
 inflammation40,41. Whole-body deletion of RAGE may thus lead to a dysbalance in the body’s AGEs levels due to 
the loss of trapping in adipose tissue, while hepatocyte-specific deletion would still allow trapping of circulating 
AGEs by RAGE in adipose tissue. Thus, the persistence of hepatosteatosis and inflammation in the liver of the 
LeptrDb−/− animals in spite of the absence of RAGE may, at least partially, be explained by a persistently high 
level of AGEs in the organism.
It has been reported that uncontrolled increase of AGEs leads to hyperexpression of RAGE with concomitant 
depletion of AGE-R1 expression and  function23,29,30,42–44, while induction of AGE-R1 overexpression has a protec-
tive effect on both AGEs accumulation and RAGE  hyperexpression27,31,44. Specifically, a recent study has suggested 
that in high-AGEs diet-induced NASH, increased RAGE downregulates the expression of AGE-R1 gene through 
Nrf2  suppression23. In the present study, in the liver of LeptrDb−/− mice, we found that the accumulation of 
AGEs and the increased RAGE levels found in obese mice were not associated with a change in AGE-R1 levels. 
This difference is possibly due to the different impact that the AGEs-diet exert on AGE receptors in comparison 
to our model of exceeding calories intake-induced NAFLD. However, the genetic deletion of RAGE in our obese 
model concomitantly led to a significant downregulation of AGE-R1 via a hereto unknown mechanism, which 
may counteract any beneficial effects of RAGE-deficiency.
In addition, Gal-3 is another important ubiquitously distributed high affinity receptor for AGEs involved 
in removal of AGEs from plasma leading to cell  activation45,46. Non-consistent effects have been reported for 
Gal-3 knockout in the liver, with either an improvement or a worsening of steatosis and liver  damage47,48. 
Although Gal-3 expression was only slightly increased in the obese LeptrDb−/− model compared to the lean 
Leptr+/+ model, RAGE-deficient obese animals showed a strong, possibly compensatory, increase of Gal-3 
expression.
Furthermore, Gal-3 has been previously involved in the activation of the NLRP3 inflammasome pathway, 
contributing to inflammatory  response49. Accordingly, studies in the liver of Gal-3 knockout mice indicate 
attenuation of inflammation, hepatocyte injury and fibrosis, and insulin  resistance26,47. In our model the con-
sistent increased gene and protein expression of Gal-3 in the RAGE−/−LeptrDb−/− mice was accompanied by 
sustained NLRP3 inflammasome pathway activation and this was paralleled by markedly increased expression 
of MyD88, an alternative inducer of NLRP3 complex to the classical NFkB pathway, whose activation was indeed 
completely suppressed by the RAGE  deletion50. Moreover, the here observed progressive increase of Gal-3 protein 
level across the experimental groups seems to positively correlate with the activation of the lipogenic SREBP1c 
pathway, with the triglyceride content, and with the grade of steatosis, as indicated by some papers on NAFLD 
and NASH in animal models and by a clinical study on liver biopsies from NAFLD  children51–53. Thus, Gal-3 
is likely to be a good candidate for the compensative trapping of circulating AGEs in the liver of obese mice in 
absence of RAGE, enhancing AGEs-induced liver damage.
On the other hand, the rising AGE levels can be counteracted by the detoxifying activity of Glo-154. In ani-
mal models of genetically induced obesity variable alterations of Glo-1 gene and protein expression have been 
described depending on the experimental conditions and the examined  tissue55,56, with generally a decrease in 
enzymatic activity that can rather be due to due to the high AGEs influx and to the exhaustion of its cofactor 
 GSH57,58. Indeed, the activation of RAGE leads to inflammation and oxidative stress with consequent depletion 
of the antioxidant tripeptide GSH. In the liver of our obese LeptrDb−/− mice, no alterations in gene or protein 
expression, neither in enzymatic activity of Glo-1 was detected in comparison to the lean controls, but deletion 
of RAGE in the LeptrDb−/− background significantly impaired Glo-1 gene expression with consequent reduced 
protein levels and compromised activity. Notably, gene expression of Glo-1 is transcriptionally regulated by the 
transcription factor Nrf2 which also controls the expression of enzymes responsible for the GSH synthesis and 
recycling. In our model, the nuclear protein levels of Nrf2 were enhanced in the obese LeptrDb−/− mice, but 
this increase was completely prevented when RAGE was deleted. This impaired nuclear translocation of Nrf2 
in absence of RAGE might account for the reduced Glo-1 expression and GSH levels and consequent reduced 
AGEs-detoxifying activity. In addition, in the obese LeptrDb−/− groups of mice, we also observed significant 
reduction in the expression of aldose reductase, an enzyme involved in the metabolism of glucose that catalyzes 
the reduction of AGEs precursors and regulate the expression of  RAGE59, with no additional alteration when 
RAGE was deleted.
This study has some limitations. First, we do not provide evidence for a direct causal role of AGEs in induc-
tion of SREBP1c and NLRP3 pathways. However, we and others have demonstrated elsewhere that inhibition 
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of AGEs production or blocking of AGE/RAGE signalling reverses both SREBP1c and NLRP3 upregulation, 
concomitantly improving steatosis and  inflammation43,60–63.
Second, although we report a clear association between the genetic deletion of RAGE and modifications of 
the AGE-detoxifying systems and AGE-receptors, this model does not allow us to disentangle whether these 
compensatory mechanisms are only at play when RAGE is deactivated before birth, or whether such compensa-
tion could also be relevant in a more acute way of inactivating RAGE.
In conclusion, despite the lacking of RAGE in the liver of LeptrDb−/− mice, high levels of intrahepatic AGEs 
were maintained, possibly caused by both a compensatory trapping exerted by Gal-3 and a reduced detoxify-
ing potential due to AGE-R1, Glo-1, and aldose reductase impairment. As a consequence, hyperactivation of 
lipogenesis, which has been previously demonstrated to be directly activated by  AGEs21,43, was enhanced, while 
the increased expression of Gal-3 contributed to both the persistent NLRP3 inflammasome activation, not 
depending on NFkB, and steatosis.
Our results confirm that AGEs might be involved in the development of NAFLD through different mecha-
nisms, involving either direct AGEs effects or various receptor-mediated signalling. However, RAGE targeting 
does not seem to be effective in the prevention of NAFLD in conditions of obesity since its deletion influences 
other AGE-receptors and AGE-detoxifying systems, indirectly demonstrating a complex tissue specific interac-
tion of these molecules.
In perspective, trying to deeply understand this reciprocal control mechanism among AGEs receptors and 
detoxifying systems will allow to identify molecular targets and therapeutic tools to modulate and prevent the 
pathogenic contribution of AGEs to hepatic metabolic disturbances.
Materials and methods
Animals. We analysed the livers of mice previously used for another study on adipose tissue. Physiological 
parameters and methods are reported in Gaens et  al.5. Briefly, obese RAGE-deficient mice (RAGE−/− Lep-
trDb−/−) were generated by crossing obese, non-insulin dependent diabetic C57BLKS-LeptrDb (LeptrDb−/−) 
(Charles River, Maastricht, the Netherlands) with RAGE−/− mice (obtained from Heidelberg University) for 
several generations. All mice were fed ad libitum with a standard control diet (catalog #D11112201; Research 
Diets Inc., New Brunswick, NJ, USA). At 13 weeks of age, lean control C57BLKS (RAGE+/+LeptrDb+/+), obese 
(RAGE+/+LeptrDb−/−) and their littermate obese RAGE-deficient (RAGE−/− LeptrDb−/−) mice were sacri-
ficed by CO2/O2 inhalation followed by exsanguination via cardiac puncture, plasma was collected and liver 
was removed and sectioned for following analysis. The animal protocol was approved by the Ethic Committee 
of Maastricht University. All animal experiments and methods were in compliance with the guidelines from the 
Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and 
follow the ARRIVE guidelines.
Markers of inflammation. Mouse inflammatory panels for interferon (IFN)-γ, tumor necrosis factor 
(TNF)-α, IL-10 assays were purchased from Meso Scale Discovery (MSD, MD, USA)5. All reagents were pro-
vided with the MSD kit, and measurements were performed according to the manufacturer’s instructions.
mRNA extracts and PCR analysis. Total RNA was extracted from liver samples using TRIzol (Invitro-
gen, Bleiswijk, the Netherlands), and was reverse transcribed with the iScript cDNA Synthesis Kit (Bio-Rad, 
Veenendaal, the Netherlands). The expression of target genes was measured quantitatively by real-time PCR 
using SYBR Green mix (Bioline, London, U.K.). All primer sets used are listed in Supplementary Table  S1. 
mRNA expression levels were normalized to two reference genes (cyclophilin A and β2-microglobulin), and 
data were analyzed with the ΔCT  method61. Data are expressed as normalized gene expression levels relative to 
wild-type RAGE+/+LeptrDb+/+mice.
Total, nuclear, and cytosolic protein extracts. Total proteins were extracted from 10% (w/v) liver 
homogenates in RIPA buffer (0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mmol/L EDTA, and 
protease inhibitors). After 40 min of incubation in ice, samples were sonicated and cleared by centrifugation at 
15,000×g at 4 °C for 40 min. Supernatants were removed and stored at − 80 °C until  use43.
Cytosolic and nuclear proteins were obtained from livers homogenized at 10% (wt/vol) in a homogenization 
buffer containing 20 mM HEPES (pH 7.9), 1 mM MgCl2, 0.5 mM EDTA, 1% Nonidet P-40, 1 mM EGTA, 1 mM 
DTT, 0.5 mM PMSF, 5 μg/mL aprotinin, 2.5 μg/mL leupeptin and 2 mM  NaVO3. Homogenates were centrifuged 
at 1000×g for 5 min at 4 °C. Supernatants were removed and centrifuged at 105,000×g at 4 °C for 40 min to obtain 
the cytosolic fraction. The pelleted nuclei were resuspended in extraction buffer containing 20 mM HEPES (pH 
7.9), 1.5 mM MgCl2, 300 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/
mL aprotinin, 2.5 μg/mL leupeptin and 2 mM  NaVO3 and incubated on ice for 30 min for high-salt extraction, 
followed by centrifugation at 15,000 g for 20 min at 4 °C. The resulting supernatants containing nuclear proteins 
were carefully removed and stored at − 80 °C58.
Protein content was determined using the Bradford assay (Bio-Rad, Hercules, CA, USA).
Western blotting analysis. Equal amounts of proteins were separated by SDS-PAGE and electrotrans-
ferred to nitrocellulose membrane (GE-Healthcare Europe, Milano, Italy). Membranes were probed with pri-
mary antibodies, listed in Supplementary Table S2, followed by incubation with appropriated horseradish per-
oxidase (HRP)-conjugated secondary antibodies (Bio-Rad). Proteins were detected with Clarity Western ECL 
substrate (Bio-Rad) and quantified by densitometry using analytic software (Image Lab; Bio-Rad; https:// www. 
bio- rad. com/ it- it/ produ ct/ image- lab- softw are). Results were normalized with respect to densitometric value 
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of mouse anti-β-actin (Santa Cruz Biotechnology) for total and cytosolic extracts and mouse anti-histone H3 
(Abcam) for nuclear  proteins43,58 and then expressed as fold of wild-type RAGE+/+LeptrDb+/+mice value.
UPLC-MSMS analysis of AGEs. To measure CML, CEL, MG-H1, and lysine, 25 μL of liver homogenates 
were subjected to a reduction step in 100 mmol/L sodium borohydride to prevent CML neo-formation. Next, 
samples were deproteinized with trifluoroacetic acid and then hydrolyzed by adding 6 N HCl to the protein pel-
let and incubated for 20 h at 90 °C. After hydrolysis, 40 μL hydrolysate and 20 μL internal standard were mixed 
in a reaction vial and evaporated to dryness under nitrogen at 70 °C and derivatized with 100 μL 1-butanol:HCl 
(3:1, v/v) for 90 min at 70 °C. Samples were then evaporated to dryness under nitrogen and redissolved in 200 
μL water. For measurement of lysine, 10 μL hydrolysate was diluted in 800 μL water. Twenty μL of this mixture 
and 20 μL internal standard was diluted in 500 μL 10 mmol/L ammonia. Derivatized CML, CEL and MG-H1, 
and underivatized lysine were analyzed by UPLC tandem MS. Protein-bound CML, CEL and MG-H1 sample 
concentrations were calculated by comparison to calibration curves. All protein-bound fractions of AGEs were 
expressed per mmol lysine to adjust for the amount of protein per  sample64.
Enzymatic activity of Glo-1. Glo-1 activity was measured in total protein liver extracts, according to 
the method of McLellan et al.65. In short, Glo-1 activity was assayed by spectrophotometry (Synergy; BioTek, 
Winooski, VT), by measuring the increase in absorbance at 240 nm as a result of the formation of S-d-lactoyl-
glutathione for 20 min.
Lipids accumulation. Neutral lipids accumulation in the liver was evaluated by Oil Red O staining on 7-μm 
liver cryostatic sections. Stained tissues were viewed under an Olympus Bx4I microscope (× 20 magnification) 
with an AxioCamMR5 photographic attachment (Zeiss, Gottingen, Germany)66. Tissue triglyceride and total 
cholesterol levels were determined on liver homogenates by standard enzymatic procedures using reagent kits 
(FAR Diagnostics, Verona, Italy).
Statistical analysis. The Shapiro–Wilk test was used to assess the normality of the variable distributions. 
One-way ANOVA followed by Bonferroni’s post-hoc test was adopted for comparison among the experimental 
groups. Data were expressed as mean ± s.e.m. Statistical tests were performed with GraphPad Prism 7.0 soft-
ware package (GraphPad Software, San Diego, CA, USA; https:// www. graph pad. com/ scien tific- softw are/ prism). 
Threshold for statistical significance was set to P < 0.05.
Materials. All compounds were purchased from Sigma Chemical, unless otherwise stated.
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